Most cited papers in Lung Cancer Research Studies

Lung Cancer Research Studies

What are the most cited papers in Lung Cancer Research Studies?

The most cited paper in Lung Cancer Research Studies is "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" (Julie Renee Brahmer et al., 2015), with 8,632 citations. Next come "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (8,331) and "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" (5,563).

Published TypeAccessAuthorsCitations

Showing 50 of 99 papers. Every paper with more than 1,376 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie Renee Brahmer et al. · New England Journal of Medicine Open access	31 May 2015	8,632
2	Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine Open access	19 Aug 2009	8,331
3	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell et al. · The Lancet Oncology Open access	30 Jan 2012	5,563
4	Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria et al. · New England Journal of Medicine Open access	18 Nov 2017	5,475
5	Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances Alice Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine Open access	13 Jul 2005	5,471
6	The biology and management of non-small cell lung cancer Roy S. Herbst, Daniel Morgensztern, CHRIS H. BOSHOFF · Nature	2018	5,116
7	Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Joan H. Schiller, David T. Harrington, Chandra Prakash Belani et al. · New England Journal of Medicine	10 Jan 2002	5,010
8	Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis Laurent Meijer et al. · Journal of Innate Immunity Open access	2016	4,999
9	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma William David Travis et al. · Journal of Thoracic Oncology Open access	20 Jan 2011	4,890
10	One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States James C. Yao, Manal M. Hassan, Alexandria T. Phan et al. · Journal of Clinical Oncology	18 Jun 2008	4,565
11	Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice Lee Kwak et al. · New England Journal of Medicine Open access	27 Oct 2010	4,517
12	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update María Reig, Alejandro Forner, Jordi Rimola et al. · Journal of Hepatology Open access	19 Nov 2021	4,345
13	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou et al. · The Lancet Oncology	25 Jul 2011	4,126
14	The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours Peter Goldstraw, John Crowley, Kari Chansky et al. · Journal of Thoracic Oncology Open access	Aug 2007	3,691
15	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn et al. · New England Journal of Medicine Open access	25 Sep 2018	3,637
16	Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain William J. Pao, Vincent A. Miller, Katerina A. Politi et al. · PLoS Medicine Open access	17 Feb 2005	3,557
17	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States Arvind N. Dasari, Chan Shen, Daniel M. Halperin et al. · JAMA Oncology Open access	27 Apr 2017	3,531
18	Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access	Jun 2013	3,429
19	Lung cancer: current therapies and new targeted treatments Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · The Lancet Open access	2 Sep 2016	3,404
20	Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors Jonathan Strosberg et al. · New England Journal of Medicine Open access	11 Jan 2017	3,307
21	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Purvish Mahendra Parikh, Joachim von Pawel et al. · Journal of Clinical Oncology	27 May 2008	3,238
22	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Lecia Van Dam Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology	Jul 2013	3,223
23	Nasopharyngeal carcinoma Yu‐Pei Chen, Anthony T.�C. Chan, Quynh‐Thu Le et al. · The Lancet	7 Jun 2019	3,186
24	A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain Roy A. Patchell, Phillip A. Tibbs, JOHN W. T. WALSH et al. · New England Journal of Medicine Open access	22 Feb 1990	3,166
25	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship Julian R. Molina, Ping Yang, Stephen D. Cassivi et al. · Mayo Clinic Proceedings Open access	May 2008	3,107
26	Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer Robert J. Ginsberg, Larry Rubinstein · The Annals of Thoracic Surgery	Sep 1995	3,055
27	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology	20 May 2003	2,899
28	A 5‐decade analysis of 13,715 carcinoid tumors Irvin Mark Modlin, Kevin D. Lye, Mark S. Kidd · Cancer	3 Feb 2003	2,758
29	Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti et al. · Journal of Clinical Oncology Open access	27 May 2008	2,709
30	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors Daniel Y. Wang et al. · JAMA Oncology Open access	18 Sep 2018	2,692
31	Lung cancer Alesha A. Thai, Benjamin J. Solomon, Lecia Van Dam Sequist et al. · The Lancet	21 Jul 2021	2,661
32	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology Open access	Sep 2016	2,650
33	Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials Laurie E. Gaspar, Charles Scott, Marvin Rotman et al. · International Journal of Radiation OncologyBiologyPhysics Open access	Mar 1997	2,570
34	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine	9 Feb 2011	2,567
35	Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA	22 Oct 2003	2,547
36	Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology	24 Aug 2009	2,525
37	Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer Solange Peters, D. Ross Camidge, Alice Tsang Shaw et al. · New England Journal of Medicine Open access	6 Jun 2017	2,523
38	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers Helena Alexandra Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research Open access	7 Mar 2013	2,517
39	Comprehensive genomic profiles of small cell lung cancer Julie George et al. · Nature Open access	10 Jul 2015	2,448
40	Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Nasser H. Hanna, Frances Alice Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology Open access	29 Apr 2004	2,445
41	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers Hisayuki Shigematsu, Lin Li, Tsuyoshi Takahashi et al. · JNCI Journal of the National Cancer Institute	Mar 2005	2,418
42	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Jonathan J. Havel, Diego Chowell, Timothy An-thy Chan · Nature reviews. Cancer ReviewOpen access	12 Feb 2019	2,398
43	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer Rafael Rosell et al. · New England Journal of Medicine Open access	19 Aug 2009	2,388
44	Congestive heart failure in patients treated with doxorubicin Sandra M. Swain, Fredrick S. Whaley, Michael S. Ewer · Cancer Open access	19 May 2003	2,328
45	Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis G Paz-Ares et al. · The Lancet 246 authors	4 Oct 2019	2,310
46	Topoisomerase I inhibitors: camptothecins and beyond Yves G. Pommier · Nature reviews. Cancer Review	22 Sep 2006	2,294
47	Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment Narjust Duma, Rafael Santana-Dávila, Julian R. Molina · Mayo Clinic Proceedings	Aug 2019	2,285
48	Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer Talia Golan, Pascal Hammel, Michele Reni et al. · New England Journal of Medicine Open access	2 Jun 2019	2,285
49	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Darren A.E. Cross et al. · Cancer Discovery Open access	4 Jun 2014	2,276
50	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Bryan J. Schneider et al. · Journal of Clinical Oncology Open access	Nov 2021	2,212

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.